Drug profile · INN
tebentafusp
KIMMTRAK
tebentafusp (KIMMTRAK) is a melanocyte protein pmel binding agent. Associated with Lacuna Pharma Pty Ltd.
EMA: approved TGA: approved Antineoplastic and immunomodulating agents (L01) L01XX75
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — tebentafusp
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 4
- Data quality
- 0.83
Quick answer
tebentafusp (KIMMTRAK) is a melanocyte protein pmel binding agent. Associated with Lacuna Pharma Pty Ltd.
Key facts
INN tebentafusp
Brand KIMMTRAK
Mechanism Melanocyte protein PMEL binding agent
Target Melanocyte protein PMEL
Therapeutic class Antineoplastic and immunomodulating agents (L01)
ATC code L01XX75
Originator Lacuna Pharma Pty Ltd
Mechanism of action
Melanocyte protein PMEL binding agent
Primary target: Melanocyte protein PMEL
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
| TGA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is tebentafusp?
tebentafusp (KIMMTRAK) is a melanocyte protein pmel binding agent. Associated with Lacuna Pharma Pty Ltd.
What is the brand name for tebentafusp?
KIMMTRAK is a marketed brand name for tebentafusp. Check FDA Drugs@FDA for the current US label holder and prescribing information.